Advertisement

Topics

Calabar AB Company Profile

03:42 EDT 20th September 2017 | BioPortfolio

Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formulations of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se


News Articles [0 Results]

None

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Physostigmine salicylate [Akorn]

Physostigmine Salicylate Injection

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Calabar AB

Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formul...

More Information about "Calabar AB" on BioPortfolio

We have published hundreds of Calabar AB news stories on BioPortfolio along with dozens of Calabar AB Clinical Trials and PubMed Articles about Calabar AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Calabar AB Companies in our database. You can also find out about relevant Calabar AB Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record